Small Cell Lung Cancer: How I Treat Extensive Stage Disease
|
|
- Christian Simon
- 5 years ago
- Views:
Transcription
1 Small Cell Lung Cancer: How I Treat Extensive Stage Disease Primo N. Lara, Jr., MD Professor of Medicine Associate Director for Translational Research
2 Pop Quiz: These deadly creatures are related in what way? You try to kill em, but they keep coming back!
3 Extensive Stage SCLC: State of the Art 2012 Platinum/Etoposide (PE) has been the standard of care for two decades Randomized trials have failed to identify more effective regimens In Japan, Cisplatin/Irinotecan (PI) is a standard Median survival time is 8-10 months, also unchanged for over 20 years The most important breakthrough in the last decade? Prophylactic cranial irradiation!
4 Prophylactic Cranial Irradiation (PCI) in Extensive SCLC PCI* No PCI HR P Value 1-year OS 27% 13% month failure free survival Symptomatic brain metastasis 23% 15.5% % 40% 0.27 <.001 * Gy in 5-12 fxs Slotman et al., NEJM 2007
5 S0124: Cisplatin/Irinotecan vs. Cisplatin/Etoposide No difference in PFS and OS Progression Free Survival Overall Survival Lara, et al. J Clin Oncol 2009 Failed to confirm Japanese results
6 Second-line SCLC therapy: Current Status 2012 Prognosis is poor Median survival 2-3 months Patients resistant to chemo (progression within 90 days) or who have received multiple prior regimens rarely respond to additional treatment Topotecan is approved as 2 nd Line therapy on basis of phase III trial vs. CAV In good performance status patients, the best option is clinical trial participation
7 Phase III Topotecan vs. CAV in Second-line SCLC Progressive SCLC > 60 days R A N D O M I Z E Topotecan 1.5 mg/m 2 x 5 days Q 21 days Cyclophosphamide 1 gm Adriamycin 45 mg/m 2 Vincristine 2 mg d1 q3 weeks Von Pawel: JCO, 1999 Primary endpoint: Response Rate
8 Phase III Topotecan vs CAV in Second-line SCLC Topotecan CAV Number Response (%) Gr 3-4 Hgb/plts (%)* 42/58 20/15 Toxic death (#) 4 3 Median survival (weeks) Symptom improvement Better - *resulting in increased transfusions Conclusion: Topotecan was at least as effective as CAV in the treatment of patients with recurrent SCLC and resulted in improved control of several symptoms Von Pawel: JCO, 1999
9 SCLC: Second Line Therapy Topotecan is approved as 2 nd Line therapy Amrubicin is a newer synthetic anthracycline Potent topoisomerase II inhibitor approved in Japan for treatment of SCLC Amrubicin and topotecan were compared as 2 nd -line treatment for SCLC patients
10 Amrubicin vs. topotecan: Randomized phase III trial 2:1 randomization N=647 Amrubicin: 40 mg/m 2 /day slow IV push over 5 min, days 1-3 of 21-day cycle Topotecan: 1.5 mg/m 2 /day IV infusion over 30 min, days 1-5 of 21-day cycle Primary Endpoint: Overall survival AMR Topo HR 95% CI P value RR (%) PFS (mo) OS (mo) Jotte, et al. ASCO 2011
11 So why has progress in SCLC been so disappointingly slow?
12 SCLC: Top Ten Reasons 1. Incomplete biologic understanding 2. Lack of biomarkers 3. Tumor heterogeneity 4. Patient heterogeneity 5. Inadequate preclinical models 6. Insufficient tumor tissue 7. Relative investigator disinterest 8. Rapid development of drug resistance 9. Lack of advocacy 10. Small (and shrinking) patient base
13 #10 Small (and shrinking!) Patient Base Lung and bronchus: 226,160 new cases per year SCLC: 25,000 30,000/year (13% of all lung cancer, decreasing in incidence) CML: 5,430; Gastric: 21,320; Myeloma: 21,700; Ovary: 22,280; HCC: 28,720 EGFR mt NSCLC: ~23,000; ALK+ NSCLC: ~9,000
14 #9 Lack of Advocacy Median Survival Median Survival 2-Year Survival Untreated Patients* Treated Patients (%) (mo) (mo) Limited disease %-45% Extensive disease %-20% * historical data SCLC is a uniformly fatal disease Lack of high profile survivors = absence of advocacy Ihde DC, et al. Cancer: Principles & Practice of Oncology. 1997; Lassen U, et al. Cancer Treatment. 1995; Soriano AF, et al. Current Cancer Therapeutics. 1998;
15 Even high profile cases do not seem to raise awareness for SCLC
16 SCLC: Top Ten Reasons 1. Incomplete biologic understanding 2. Lack of biomarkers 3. Tumor heterogeneity 4. Patient heterogeneity 5. Inadequate preclinical models 6. Insufficient tumor tissue 7. Relative investigator disinterest 8. Rapid development of drug resistance 9. Lack of advocacy 10. Small (and shrinking) patient base
17 #8 Drug Resistance Despite initial high response to chemotherapy, resistance rapidly emerges Cisplatin resistance studied widely Many candidate modulators: ERCC1, XRCC1, etc. Examples of other chemoresistance studies: ECM proteins (Sethi, Nature Med 1999) GRP78 (Wang, BMC Cancer 2008) CXCR4 and nicotine (Garcia, Tox Sci 2010) Micro RNAs (Guo, Eur J Cancer 2010) and countless others
18 #8 Drug Resistance Lawson, Cancer Res 2011 Novel Determinants of Etoposide Resistance: NKX.2 and DNA polymerase beta
19 SCLC: Top Ten Reasons 1. Incomplete biologic understanding 2. Lack of biomarkers 3. Tumor heterogeneity 4. Patient heterogeneity 5. Inadequate preclinical models 6. Insufficient tumor tissue 7. Relative investigator disinterest 8. Rapid development of drug resistance 9. Lack of advocacy 10. Small (and shrinking) patient base
20 #7 Relative Investigator Disinterest Active studies on clinicaltrials.gov* SCLC 120 Ovarian 522 Myeloma CML 107 *As of March 1, 2012
21 SCLC: Top Ten Reasons 1. Incomplete biologic understanding 2. Lack of biomarkers 3. Tumor heterogeneity 4. Patient heterogeneity 5. Inadequate preclinical models 6. Insufficient tumor tissue 7. Relative investigator disinterest 8. Rapid development of drug resistance 9. Lack of advocacy 10. Small (and shrinking) patient base
22 #6 Insufficient Tumor Tissue Few surgical resections in SCLC Most diagnostic specimens FNA or cytologic Serial biopsies exceedingly rare Thus, limited tumor specimens available for research
23
24 SCLC: Top Ten Reasons 1. Incomplete biologic understanding 2. Lack of biomarkers 3. Tumor heterogeneity 4. Patient heterogeneity 5. Inadequate preclinical models 6. Insufficient tumor tissue 7. Relative investigator disinterest 8. Rapid development of drug resistance 9. Lack of advocacy 10. Small (and shrinking) patient base
25 #5 Inadequate Preclinical Models Expression of tumor-specific genes in primary SCLC and xenografts lost during transition to tissue culture Gene expression NOT regained when tumors were re-established as secondary xenografts Cancer Res, 2009
26 SCLC: Top Ten Challenges 1. Incomplete biologic understanding 2. Lack of biomarkers 3. Tumor heterogeneity 4. Patient heterogeneity 5. Inadequate preclinical models 6. Insufficient tumor tissue 7. Relative investigator disinterest 8. Rapid development of drug resistance 9. Lack of advocacy 10. Small (and shrinking) patient base
27 Common Arm Comparative Toxicity Analysis: JCOG 9511 vs. SWOG 0124 Cisplatin + Etoposide Cisplatin + Irinotecan Grade 3 Toxicity J9511 S0124 p-value J9511 S0124 p-value Infection 3 (4%) 52 (16%) (5%) 36 (11%) 0.23 Neutropenia 71 (92%) 220 (68%) < (65%) 107 (34%) < Leukopenia 41 (53%) 109 (34%) (27%) 57 (18%) 0.04 Anemia 25 (32%) 39 (12%) < (28%) 18 (6%) < Lara, et al. Cancer 2010
28 Common Arm Comparative Efficacy Analysis: JCOG 9511 vs. SWOG 0124 Cisplatin + Etoposide Cisplatin + Irinotecan Efficacy Measure J9511 S0124 p-value J9511 S0124 p-value Response Rate Progression-free Survival, median (months) 68% 57% % 60% < Lara, et al. Cancer 2010
29 Why were S0124 and J9511 results divergent? Early stopping of the J9511 trial Smaller sample size of J9511 may have significantly overestimated the treatment effect, which diminishes when the number of events accrued is large Imbalances in the distribution of patient characteristics in J9511 Fewer patients with performance status of 2, more women (who historically do better than men), and fewer brain metastases Inherent genetic differences that exist between populations Single nucleotide polymorphisms of genes involved in chemotherapy metabolism or transport may underlie racial differences Lara, et al. J Clin Oncol 2009
30 SCLC: Top Ten Reasons 1. Incomplete biologic understanding 2. Lack of biomarkers 3. Tumor heterogeneity 4. Patient heterogeneity 5. Faulty preclinical models 6. Insufficient tumor tissue 7. Relative investigator disinterest 8. Rapid development of drug resistance 9. Lack of advocacy 10. Small (and shrinking) patient base
31 the mesenchymal compartment of the tumor is generated from a separate subclone during the tumorigenic process, providing the tumor cell population as a whole with new capabilities such as metastatic potential. Cancer Cell 2011
32 SCLC: Top Ten Reasons 1. Incomplete biologic understanding 2. Lack of biomarkers 3. Tumor heterogeneity 4. Patient heterogeneity 5. Inadequate preclinical models 6. Insufficient tumor tissue 7. Relative investigator disinterest 8. Rapid development of drug resistance 9. Lack of advocacy 10. Small (and shrinking) patient base
33 #2 Lack of Biomarkers Precise cellular origin of SCLC is unknown May arise from bronchial mucosa Can undergo both neuroendocrine (NE) and non-ne differentiation: suggests common epithelial ancestor Stem cells? Reactivation of Hedgehog signaling in lung stem cells leads to NE differentiation Gazdar, Science 1985; Stovold, Lung Cancer 2011
34 Revisiting Neuroendocrine Biomarkers in SCLC POMC: hormonal precursor elevated in 30% of SCLC; potential role as secreted biomarker? Other markers: Pro-GRP NSE Synaptophysin CD56 Stovold, Lung Cancer 2011
35 CD56 as biomarker and therapeutic target CD56 a neural cell adhesion molecule (NCAM) Expressed extensively (~100%) on SCLC cell surface IMGN901 is an antibody-drug conjugate (ADC) designed to deliver a potent tubulin-acting agent (DM1) specifically to CD56- expressing cells IMGN901 has preclinical activity as single agent and in combination with platinum/etoposide in SCLC Anti-CD56 antibody (humanized IgG1) Engineered disulfide linker Randomized phase II trial of carbo/vp16 +/- IMGN901 in SCLC ongoing Conjugated to DM1 Derivative of maytansine Antimitotic inhibits tubulin polymerization
36 SCLC: Top Ten Reasons 1. Incomplete biologic understanding 2. Lack of biomarkers 3. Tumor heterogeneity 4. Patient heterogeneity 5. Inadequate preclinical models 6. Insufficient tumor tissue 7. Relative investigator disinterest 8. Rapid development of drug resistance 9. Lack of advocacy 10. Small (and shrinking) patient base
37 Fundamental Issue in SCLC Biology No actionable driver mutations OFF ON Tumor Suppressor Oncogene
38 SCLC Biologic Dilemma Oncogenes Not reliably identified in SCLC Driver vs. passenger mutations Recent advances in other solid tumors: oncogenes as targets Inherently druggable EGFR, BCR-ABL, ckit, BRAF, etc cmet mutation in SCLC previously described (Salgia): potential target
39 SCLC Biologic Dilemma Tumor Suppressor Genes Commonly seen in SCLC P53, RB Deleted, silenced, inactivated Not easily druggable Need to instead target effector pathways VEGF, cell cycle kinases, signal transduction
40 Small Cell Lung Cancer 3p (del) Molecular Profile p53 mutations: 80-90% Rb abnormalities: 100% High Expression of c-kit* High Expression of BCL2* Biologic Behavior High cellular proliferation Short cell cycle time Rapid doubling time Early metastases Chemo-radiation sensitive * Oncogenes
41 Median OS = 3 months JTO 2006 Tumor tissue not available for further interrogation
42 ABT-263 in SCLC Phase I/II Monotherapy Thrombocytopenia doselimiting Tolerable Limited efficacy as monotherapy Phase I in combination with cisplatin and etoposide Cisplatin 75mg/m 2 D1, Etoposide 100mg/m 2 D1-3 ABT-263 doses explored: Starting dose: 150mg D1-5; adjusted to 150mg D1-3 Adverse effects: Grade 4 neutropenia, neutropenic fever 39 patients with recurrent SCLC; 26 evaluable: - 1 PR Closed due to futility - 9 SD (23%) - 16 PD Hann/Rudin, Targeted Therapies 2012
43 Obatoclax in SCLC Phase 2b Trial Design R Investigational Arm (CbEOb) * Carboplatin AUC 5 IV day 1 Etoposide 100 mg/m2 days 1, 2, 3 Obatoclax 30 mg/3 hr days 1, 2 and 3 Tx every 3 wks X 6, followed by Maintenance obatoclax [same schedule until PD] Control Arm (CbE) * Carboplatin AUC 5 IV day 1 Etoposide 100 mg/m2 days 1, 2, 3 Tx every 3 wks X 6 * PCI: permissible in both arms Langer, ASCO 2011
44 Response Rate Analysis* PS 0-2 CR/PR CbEOb CbE Total Odds Ratios 50/77 65% 42/78 55% P value (Fisher s; 1- sided) PS 0-2 CR/PR/SD 64/77 83% 54/78 69% PS 0-1 CR/PR 47/69 68% 41/72 57% PS 0-1 CR/PR/SD 61/69 88% 53/72 74% All responses, including SD, confirmed by 2 nd evaluation 6 + wks later CR/PR/SD = Disease Control Rate Langer, ASCO 2011
45 Percent survival Kaplan-Meier Actuarial Estimated Survival Median 9.8 mos 10.5 mos CbE CbeOb CE CEO Overall H.R CEOb/CE P value (1-sided): Time
46 Targeting Pathways in Absence of Actionable Oncogenic Mutations Example: PI3K/AKT/mTOR pathway is defective in SCLC pakt expression = 70% pten mutations = 15% D Angelo, Cancer Biol & Ther 2010; Krystal, Mol Ther 2002
47 SCLC Cell Line Panel Cell line p53 RB PTEN PI3K EGFR KRAS BRAF ALK H526 Mt Mt wt wt wt wt wt wt H69 Mt Mt wt Mt wt wt wt wt H2196 Mt Mt Mt wt wt wt wt wt Mack lab, UC Davis *Provided by Cancer Genome Project (Sanger Institute)
48 CI CI Combination Indices (CI) show additivity or synergy for Topotecan + MK Fa-CI plot H526: PTEN wt, PI3K wt Fa-CI plot H69: PI3Kmt Effect Effect Combination CI = 1.0 ED25 CI Values Combination CI = 1.0 ED25 CI Values ED ED ED ED Median Effect Analysis Unpublished data: Mack lab, UC Davis
49 Conclusions SCLC presents both universal and unique challenges to drug development Investments in SCLC research and therapy remain underwhelming Defining biology = optimizing treatment
50 LOST IN TRANSLATION
LUNG CANCER Incidence of major histologic types*
LUNG CANCER Incidence of major histologic types* 5% other Small-cell carcinoma Adenocarcinoma 15% Large-cell carcinoma Adapted from Ihde DC, et al. Cancer: Principles & Practice of Oncology. 5th ed. 1997.
More informationLung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We
Lung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We Edward Garon, MD, MS Associate Professor Director- Thoracic Oncology Program David
More informationStato dell arte del. Antonio ROSSI, MD. Division of Medical Oncology, S.G. MOSCATI HOSPITAL, AVELLINO - ITALY
Stato dell arte del trattamento del microcitoma Antonio ROSSI, MD Division of Medical Oncology, S.G. MOSCATI HOSPITAL, AVELLINO - ITALY Truly has become small. Last session/day in all meetings One chemo
More informationCombining Lurbinectedin and Doxorubicin The UCLH Experience in Small Cell Lung Cancer
Combining Lurbinectedin and Doxorubicin The UCLH Experience in Small Cell Lung Cancer Dr Martin Forster MD PhD Clinical Senior Lecturer in Experimental Cancer Medicine Consultant in Medical Oncology UCL
More informationDebate 1 Are treatments for small cell lung cancer getting better? No:
Debate 1 Are treatments for small cell lung cancer getting better? No: Taofeek Owonikoko, MD, PhD Associate Professor Department of Hematology & Medical Oncology Winship Cancer Institute of Emory University
More informationSCLC: Developments in systemic treatment
SCLC: Developments in systemic treatment Egbert F. Smit, Dept. Pulmonary Diseases, Vrije Universiteit Medisch Centrum, Amsterdam, The Netherlands Staging Outline First line treatment Second line treatment
More informationCitation Cancer Management and Research, 2(1
NAOSITE: Nagasaki University's Ac Title Author(s) Efficacy and safety of amrubicin hy small cell lung cancer Ogawara, Daiki; Fukuda, Minoru; Nak Citation Cancer Management and Research, 2(1 Issue Date
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationUpdate on Limited Small Cell Lung Cancer. Laurie E Gaspar MD, MBA Prof/Chair Radiation Oncology University of Colorado Denver
Update on Limited Small Cell Lung Cancer Laurie E Gaspar MD, MBA Prof/Chair Radiation Oncology University of Colorado Denver Objectives - Limited Radiation Dose Radiation Timing Radiation Volume PCI Neurotoxicity
More informationSmall cell lung cancer (SCLC) accounts for approximately
ORIGINAL ARTICLE A Meta-Analysis of Randomized Controlled Trials Comparing Irinotecan/Platinum with Etoposide/Platinum in Patients with Previously Untreated Extensive-Stage Small Cell Lung Cancer Jingwei
More informationUpdate on Small Cell Lung Cancer
Welcome to Master Class for Oncologists Session 4: 10:00 AM - 10:45 AM San Francisco, CA October 23, 2009 Speaker: Bruce E. Johnson, MD Professor of Medicine, Dana-Farber Cancer Institute and Harvard Medical
More informationSmall Cell Lung Cancer What we have now?
Small Cell Lung Cancer What we have now? Chunxue Bai, M.D., Ph.D. Chair, Chinese Alliance against Lung Cancer Shanghai Respiratory Research Institute Department of Pulmonary Medicine Zhongshan Hospital,
More informationHDAC Inhibitors and PARP inhibitors. Suresh Ramalingam, MD Associate Professor Chief of Thoracic Oncology Emory University School of Medicine
HDAC Inhibitors and PARP inhibitors Suresh Ramalingam, MD Associate Professor Chief of Thoracic Oncology Emory University School of Medicine Histone Acetylation HAT Ac Ac Ac Ac HDAC Ac Ac Ac Ac mrna DACs
More informationToxicity by Age Group. Old Factor 1: Age. Disclosures. Predicting survival in metastatic colorectal cancer. Personalized Medicine - Decision Tools -
Disclosures Predicting survival in metastatic colorectal cancer Daniel Sargent, PhD Mayo Clinic Consulting activities Amgen Pfizer Roche/Genentech Sanofi-Aventis Genomic Health Personalized Medicine -
More informationNovel Chemotherapy Agents for Metastatic Breast Cancer. Joanne L. Blum, MD, PhD Baylor-Sammons Cancer Center Dallas, TX
Novel Chemotherapy Agents for Metastatic Breast Cancer Joanne L. Blum, MD, PhD Baylor-Sammons Cancer Center Dallas, TX New Chemotherapy Agents in Breast Cancer New classes of drugs Epothilones Halichondrin
More informationCALGB Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer
CALGB 30610 Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer Jeffrey A. Bogart Department of Radiation Oncology Upstate Medical University Syracuse, NY Small Cell Lung Cancer Estimated 33,000
More informationLung Cancer Epidemiology. AJCC Staging 6 th edition
Surgery for stage IIIA NSCLC? Sometimes! Anne S. Tsao, M.D. Associate Professor Director, Mesothelioma Program Director, Thoracic Chemo-Radiation Program May 7, 2011 The University of Texas MD ANDERSON
More informationRTOG Lung Cancer Committee 2012 Clinical Trial Update. Wally Curran RTOG Group Chairman
RTOG Lung Cancer Committee 2012 Clinical Trial Update Wally Curran RTOG Group Chairman 1 RTOG Lung Committee: Active Trials Small Cell Lung Cancer Limited Stage (Intergroup Trial) Extensive Stage (RTOG
More informationTwo Cycles of Chemoradiation: 2 Cycles is Enough. Concurrent Chemotherapy / RT Regimens
1 Two Cycles of Chemoradiation: 2 Cycles is Enough Heather Wakelee, M.D. Assistant Professor of Medicine, Oncology Stanford University Concurrent Chemotherapy / RT Regimens Cisplatin 50 mg/m 2 on days
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationSmall Cell Lung Cancer (SCLC): Update in Therapy. Anne Traynor, MD March 1, 2010
Small Cell Lung Cancer (SCLC): Update in Therapy Anne Traynor, MD March 1, 2010 Small Cell Lung Cancer (SCLC) 12% of lung cancer Strongest epi link with smoking Very high growth fraction Propensity for
More informationCurrent Approaches for Limited Small Cell Lung Cancer. Laurie E Gaspar MD, MBA Prof/Chair Radiation Oncology University of Colorado Denver
Current Approaches for Limited Small Cell Lung Cancer Laurie Gaspar MD, MBA Prof/Chair Radiation Oncology University of Colorado Denver Can we improve or personalize treatment? Limited Histology/molecular
More information2 nd line Therapy and Beyond NSCLC. Alan Sandler, M.D. Oregon Health & Science University
2 nd line Therapy and Beyond NSCLC Alan Sandler, M.D. Oregon Health & Science University Treatment options for advanced or metastatic (stage IIIb/IV) NSCLC Suitable for chemotherapy Diagnosis Unsuitable/unwilling
More informationOMP-305B83: A Novel, Potent DLL4 & VEGF Targeting Bispecific Antibody for the Treatment Of Solid Tumors
OMP-305B83: A Novel, Potent DLL4 & VEGF Targeting Bispecific Antibody for the Treatment Of Solid Tumors Jakob Dupont MD MA CMO, SVP: OncoMed Pharmaceuticals Adjunct Clinical Faculty: Stanford University
More informationImmunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System
Immunotherapy for Breast Cancer Aurelio B. Castrellon Medical Oncology Memorial Healthcare System Conflicts Research support : Cascadian therapeutics, Puma biotechnology, Odonate therapeutics, Pfizer,
More informationDisease progression after initial platinum-based chemotherapy
Original Article Relevance of Platinum-Sensitivity Status in Relapsed/Refractory Extensive-Stage Small-Cell Lung Cancer in the Modern Era A Patient-Level Analysis of Southwest Oncology Group Trials Primo
More informationAntiangiogenic Agents in NSCLC Where are we? Which biomarkers? VEGF Is the Only Angiogenic Factor Present Throughout the Tumor Life Cycle
Antiangiogenic Agents in NSCLC Where are we? Which biomarkers? Martin Reck Department e t of Thoracic c Oncology ogy Hospital Grosshansdorf Germany VEGF Is the Only Angiogenic Factor Present Throughout
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationMedical Treatment of Advanced Lung Cancer
Medical Treatment of Advanced Lung Cancer Oncology for Scientists April 26, 2018 Edwin Yau, MD., Ph.D. Assistant Professor of Oncology Department of Medicine Department of Cancer Genetics and Genomics
More informationTriple Negative Breast Cancer. Eric P. Winer, MD Dana-Farber Cancer Institute Harvard Medical School Boston, MA October, 2008
Triple Negative Breast Cancer Eric P. Winer, MD Dana-Farber Cancer Institute Harvard Medical School Boston, MA October, 2008 Triple Negative Breast Cancer 15% 25% Triple Negative 20% HER2+ ER+ Low Grade
More informationTratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón
Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón Santiago Ponce Aix Servicio Oncología Médica Hospital Universitario 12 de Octubre Madrid Stage III: heterogenous disease
More information11/21/2009. Erlotinib in KRAS Mt patients. Bevacizumab in Squamous patients
Decision-Making in Non-Small Cell Lung Cancer (NSCLC): Moving from Empiric to Personalized & Molecular-based Therapy David R. Gandara, MD University of California Davis Cancer Center Disclosures Research
More informationLung cancer is the most common cause of cancer-related
GUIDELINES Chemotherapy for Relapsed Small Cell Lung Cancer: A Systematic Review and Practice Guideline Susanna Cheng, MD,* William K. Evans, MD, Denise Stys-Norman, PgDip, Frances A. Shepherd, MD, and
More informationCancer Cell Research 14 (2017)
Available at http:// www.cancercellresearch.org ISSN 2161-2609 Efficacy and safety of bevacizumab for patients with advanced non-small cell lung cancer Ping Xu, Hongmei Li*, Xiaoyan Zhang Department of
More informationSmall cell lung cancer (SCLC) comprises approximately
Original Article Efficacy and Toxicity of Belotecan for Relapsed or Refractory Small Cell Lung Cancer Patients Gun Min Kim, MD,* Young Sam Kim, MD, PhD, Young Ae Kang, MD, PhD, Jae-Heon Jeong, MD, Sun
More informationDR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID
DR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID RESUMEN DE ARTICULOS THERESA BOLERO 3 NOAH UP-DATE GEPAR SIXTO RADIOTHERAPY EBCTCG CTCs MISCELANEAS Lancet Oncol 2014;
More informationNew Drug development and Personalized Therapy in The Era of Molecular Medicine
New Drug development and Personalized Therapy in The Era of Molecular Medicine Ramesh K. Ramanathan MD Virginia G. Piper Cancer Center Translational Genomics Research Institute Scottsdale, AZ Clinical
More informationTHERAPY OF SMALL-CELL LUNG CANCER Peter Berzinec Specialised Hospital of St Zoerardus Zobor Teaching Base of the Slovak Medical University Nitra,
THERAPY OF SMALL-CELL LUNG CANCER Peter Berzinec Specialised Hospital of St Zoerardus Zobor Teaching Base of the Slovak Medical University Nitra, Slovakia Lancet. 1966;2(7471):979-86. First standard treatment:
More informationCurrent state of upfront treatment for newly diagnosed advanced ovarian cancer
Current state of upfront treatment for newly diagnosed advanced ovarian cancer Ursula Matulonis, M.D. Associate Professor of Medicine, HMS Program Leader, Medical Gyn Oncology Dana-Farber Cancer Institute
More informationSystemic Therapy for Small Cell Lung Cancer Paul A. Bunn, Jr, MD, Dudley Professor, Univ. of Colorado Cancer Center, Aurora, CO, USA
Systemic Therapy for Small Cell Lung Cancer Paul A. Bunn, Jr, MD, Dudley Professor, Univ. of Colorado Cancer Center, Aurora, CO, USA Consultant: Amgen, Allos, AstraZeneca, Abraxis, Bayer, Biodesix, Boehringer-
More informationBelotecan and Cisplatin Combination Chemotherapy for Previously Untreated Extensive-Disease Small Cell Lung Cancer
J Lung Cancer 2010;9(1):15-19 Belotecan and Cisplatin Combination Chemotherapy for Previously Untreated Extensive-Disease Small Cell Lung Cancer Purpose: Belotecan (Camtobell R ; Chong Keun Dang Co., Seoul,
More informationCorporate Overview. May 2017 NASDAQ: CYTR
Corporate Overview May 2017 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER MATERIALLY
More informationComprehensive Genomic Profiling, in record time. Accurate. Clinically Proven. Fast.
Comprehensive Genomic Profiling, in record time Accurate. ly Proven. Fast. PCDx advantages Comprehensive genomic profiling, in record time PCDx Comprehensive Genomic Profiling (CGP) provides precise information
More informationES-SCLC Joint Case Conference. Anthony Paravati Adam Yock
ES-SCLC Joint Case Conference Anthony Paravati Adam Yock Case 57 yo woman with 35 pack year smoking history presented with persistent cough and rash Chest x-ray showed a large left upper lobe/left hilar
More informationLUNG CANCER. pathology & molecular biology. Izidor Kern University Clinic Golnik, Slovenia
LUNG CANCER pathology & molecular biology Izidor Kern University Clinic Golnik, Slovenia 1 Pathology and epidemiology Small biopsy & cytology SCLC 14% NSCC NOS 4% 70% 60% 50% 63% 62% 61% 62% 59% 54% 51%
More informationEGFR inhibitors in NSCLC
Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance
More informationNew targets in endometrial and ovarian cancer
New targets in endometrial and ovarian cancer SAMO Interdisciplinary Workshop on Gynecologic Tumors Luzern, January 16-17, 2016 C. Sessa IOSI Bellinzona Outline New targets in ovarian cancer - Cell cycle
More informationCUP: Treatment by molecular profiling
CUP: Treatment by molecular profiling George Pentheroudakis Professor of Oncology Medical School, University of Ioannina Greece Chair, ESMO Guidelines September 2018 Enterprise Interest No disclosures.
More informationHOW TO GET THE MOST INFORMATION FROM A TUMOR BIOPSY
HOW TO GET THE MOST INFORMATION FROM A TUMOR BIOPSY 7 TH Annual New York Lung Cancer Symposium Saturday, November 10, 2012 William D. Travis, M.D. Attending Thoracic Pathologist Memorial Sloan Kettering
More informationLUNG CANCER. Agnieszka Słowik, MD. Department of Oncology, University Hospital in Cracow Jagiellonian University
LUNG CANCER Agnieszka Słowik, MD Department of Oncology, University Hospital in Cracow Jagiellonian University Epidemiology Most common malignancy worldwide Place of lung cancer among other malignancies
More informationChemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC)
Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC) Jeffrey Crawford, MD George Barth Geller Professor for Research in Cancer Co-Program Leader, Solid Tumor Therapeutics Program
More informationA Phase 2 Trial of Voreloxin (SNS-595) in Platinum - Resistant Epithelial Ovarian Cancer
A Phase Trial of Voreloxin (SNS-595) in Platinum - Resistant Epithelial varian Cancer William McGuire, M.D. Medical Director Harry and Jeanette Weinberg Cancer Institute November 6, 008 1 Voreloxin: First-In-Class
More informationLung Cancer Case. Since the patient was symptomatic, a targeted panel was sent. ALK FISH returned in 2 days and was positive.
Lung Cancer Case Jonathan Riess, M.D. M.S. Assistant Professor of Medicine University of California Davis School of Medicine UC Davis Comprehensive Cancer Center 63 year-old woman, never smoker, presents
More informationGASTRIC & PANCREATIC CANCER
GASTRIC & PANCREATIC CANCER ASCO HIGHLIGHTS 2005 Fadi Sami Farhat, MD Head of Hematology Oncology Division Hammoud Hospital University Medical Center Saida Lebanon Tel: +961 3 753 155 E-Mail: drfadi@drfadi.org
More informationMaintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse?
Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse? Mark A. Socinski, MD Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive
More informationRole of Prophylactic Cranial Irradiation in Small Cell Lung Cancer
Role of Prophylactic Cranial Irradiation in Small Cell Lung Cancer Kazi S. Manir MD,DNB,ECMO,PDCR Clinical Tutor Department of Radiotherapy R. G. Kar Medical College and Hospital, Kolkata SCLC 15% of lung
More informationChanging demographics of smoking and its effects during therapy
Changing demographics of smoking and its effects during therapy Egbert F. Smit MD PhD. Dept. Pulmonary Diseases, Vrije Universiteit Medical Centre, Amsterdam, The Netherlands Smoking prevalence adults
More informationCombined Modality Therapy State of the Art. Everett E. Vokes The University of Chicago
Combined Modality Therapy State of the Art Everett E. Vokes The University of Chicago What we Know Some patients are cured (20%) Induction and concurrent chemoradiotherapy are each superior to radiotherapy
More informationProphylactic Cranial Irradiation and Thoracic Radiotherapy in Extensive Stage Small-Cell Lung Cancer
Prophylactic Cranial Irradiation and Thoracic Radiotherapy in Extensive Stage Small-Cell Lung Cancer Dr Neil Bayman Consultant Clinical Oncology ESMO-Christie Preceptorship Programme in Lung Cancer, March
More informationTable Selected Clinical Trials of Anti-Angiogenesis Therapy in Gynecologic Malignancies
Table Selected Clinical Trials of Anti-Angiogenesis Therapy in Gynecologic Malignancies Uterus Study N Eligibility Regimen RR (No. of Responses) Median OS Grade 3/4 Toxicities Nimeiri et al[42] Total:
More informationDALLA CAPECITABINA AL TAS 102
DALLA CAPECITABINA AL TAS 102 Milano 29 settembre 2016 LE PROSPETTIVE NELLA RICERCA Armando Santoro Humanitas Cancer Center THE 1,2.AND 3 LINE CHEMOTHERAPY IN CRC M BEVACIZUMAB AFLIBERCET RAS wt RAS mu
More informationRandomized Phase III Trials of Intravenous vs. Intraperitoneal Therapy in Optimal Ovarian Cancer
Randomized Phase III Trials of Intravenous vs. Intraperitoneal Therapy in Optimal Ovarian Cancer Deborah K. Armstrong, M.D. Associate Professor of Oncology, Gynecology and Obstetrics Development of Intraperitoneal
More informationEdith A. Perez, Ahmad Awada, Joyce O Shaughnessy, Hope Rugo, Chris Twelves, Seock-Ah Im, Carol Zhao, Ute Hoch, Alison L. Hannah, Javier Cortes
BEACON: A Phase 3 Open-label, Randomized, Multicenter Study of Etirinotecan Pegol (EP) versus Treatment of Physician s Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously
More informationOncologist. The. ASCO 2000: Critical Commentaries. Lung Cancer Highlights THOMAS J. LYNCH, JR. ABSTRACT
The Oncologist ASCO 2000: Critical Commentaries Lung Cancer Highlights THOMAS J. LYNCH, JR. Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA Key Words. Small cell lung cancer Non-small
More informationPersonalized Medicine: Lung Biopsy and Tumor
Personalized Medicine: Lung Biopsy and Tumor Mutation Testing Elizabeth H. Moore, MD Personalized Medicine: Lung Biopsy and Tumor Mutation Testing Genomic testing has resulted in a paradigm shift in the
More informationSMALL CELL LUNG CANCER Updated June 2018 by Dr. Kirstin Perdrizet (PGY-5 Medical Oncology Resident, University of Toronto)
SMALL CELL LUNG CANCER Updated June 2018 by Dr. Kirstin Perdrizet (PGY-5 Medical Oncology Resident, University of Toronto) Reviewed by Dr. Adrian Sacher (Staff Medical Oncologist, Princess Margaret Cancer
More informationAdjuvant Chemotherapy
State-of-the-art: standard of care for resectable NSCLC Adjuvant Chemotherapy JY DOUILLARD MD PhD Professor of Medical Oncology Integrated Centers of Oncology R Gauducheau University of Nantes France Adjuvant
More informationCarcinosarcoma Trial rial in s a in rare malign rare mali ancy
Carcinosarcoma Trials in a rare malignancy BACKGROUND Rare and highly aggressive epithelial malignancies Biphasic tumors with epithelial and mesenchymal components Uterine carcinomas (UCS) uncommon with
More informationpatients in the era of
Communicating with cancer patients in the era of personalized medicine September 9 th, 2017 Gerald Prager, M.D. Comprehensive Cancer Center Vienna Medical University of Vienna, Austria Gerald Prager, M.D.
More informationPrecision Genetic Testing in Cancer Treatment and Prognosis
Precision Genetic Testing in Cancer Treatment and Prognosis Deborah Cragun, PhD, MS, CGC Genetic Counseling Graduate Program Director University of South Florida Case #1 Diana is a 47 year old cancer patient
More informationG1 Corporate Overview March 11, 2019
G1 Corporate Overview March 11, 2019 www.g1therapeutics.com NASDAQ: GTHX 1 Forward-looking statements This presentation and the accompanying oral commentary contain forward-looking statements within the
More informationΚίκα Πλοιαρχοπούλου. Παθολόγος Ογκολόγος Ευρωκλινική Αθηνών
Κίκα Πλοιαρχοπούλου Παθολόγος Ογκολόγος Ευρωκλινική Αθηνών Time (months) Survival outcomes in mcrc have progressively improved over the past two decades Treatment options for many patients Multidisciplinary
More informationSmall Cell Lung Cancer Case Presentations UCSF/UCD Thoracic Oncology Conference
Small Cell Lung Cancer Case Presentations UCSF/UCD Thoracic Oncology Conference Matthew Gubens, MD Heather Wakelee, MD Extensive Stage SCLC Stanford University School of Medicine November 21, 2009 67 yo
More informationALK Fusion Oncogenes in Lung Adenocarcinoma
ALK Fusion Oncogenes in Lung Adenocarcinoma Vincent A Miller, MD Associate Attending Physician, Thoracic Oncology Service Memorial Sloan-Kettering Cancer Center New York, New York The identification of
More informationTargeting the Oncogenic Pathway as Opposed to the Primary Tumor Site: HER2 as an Example
Targeting the Oncogenic Pathway as Opposed to the Primary Tumor Site: HER2 as an Example Dennis J Slamon, MD, PhD Professor of Medicine Chief, Division of Hematology/Oncology; Director of Clinical/Translational
More informationThe 2010 Gastrointestinal Cancers Symposium Oral Abstract Session: Cancers of the Pancreas, Small Bowel and Hepatobilliary Tract
The 2010 Gastrointestinal Cancers Symposium : Cancers of the Pancreas, Small Bowel and Hepatobilliary Tract Abstract #131: Phase I study of MK 0646 (dalotuzumab), a humanized monoclonal antibody against
More informationpresentation session & clinical Keith T. Flaherty, M.D. Abramson Cancer Center of the University of Pennsylvania
Melanoma: highlights from the oral presentation session & clinical science symposium at ASCO 2009 Keith T. Flaherty, M.D. Abramson Cancer Center of the University of Pennsylvania Abstracts to be discussed
More informationASCO 2018 Investor Meeting
ASCO 2018 Investor Meeting June 4, 2018 1 Forward-Looking Information This presentation contains statements about the Company s future plans and prospects that constitute forward-looking statements for
More informationImmune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment
Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment 1 Introductions Peter Langecker, MD, PhD Executive Medical Director, Global Oncology Clinipace Worldwide Mark Shapiro Vice President
More informationImmunotherapy in the clinic. Lung Cancer. Marga Majem 20 octubre 2017
Immunotherapy in the clinic. Lung Cancer Marga Majem 20 octubre 2017 mmajem@santpau.cat Immunotherapy in the clinic. Lung Cancer Agenda Where we come from? Immunotherapy in Second line Immunotherapy in
More informationMaintenance paradigm in non-squamous NSCLC
Maintenance paradigm in non-squamous NSCLC L. Paz-Ares Hospital Universitario Virgen del Rocío Sevilla Agenda Theoretical basis The data The comparisons Agenda Theoretical basis The data The comparisons
More informationGenomic tests to personalize therapy of metastatic breast cancers. Fabrice ANDRE Gustave Roussy Villejuif, France
Genomic tests to personalize therapy of metastatic breast cancers Fabrice ANDRE Gustave Roussy Villejuif, France Future application of genomics: Understand the biology at the individual scale Patients
More informationMultiple Myeloma Updates 2007
Multiple Myeloma Updates 2007 Brian Berryman, M.D. Multiple Myeloma Updates 2007 Goals for today: Understand the staging systems for myeloma Understand prognostic factors in myeloma Review updates from
More informationWhat s New in Colon Cancer? Therapy over the last decade
What s New in Colon Cancer? 9/19/2014 Michael McNamara, MD Therapy over the last decade Cytotoxic chemotherapy - 5FU ( Mayo, Roswell, Infusional) - Xeloda (01 ) - Oxaliplatin (02 ) - Irinotecan (96 ) Anti-
More informationChoosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer
Choosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer Jyoti D. Patel, MD Associate Professor Feinberg School of Medicine Robert H Lurie Comprehensive Cancer Center Northwestern
More informationNSCLC: immunotherapy as a first-line treatment. Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To)
NSCLC: immunotherapy as a first-line treatment Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To) The 800-pound gorilla Platinum-based chemotherapy is the SOC for 1st-line therapy in
More informationInvestor Call. May 19, Nasdaq: IMGN
Investor Call May 19, 2017 Nasdaq: IMGN Forward-Looking Statements This presentation includes forward-looking statements based on management's current expectations. These statements include, but are not
More informationPersonalized Medicine for Advanced NSCLC in East Asia
Personalized Medicine for Advanced NSCLC in East Asia - Update treatment strategy for NSCLC based on Japanese clinical practice guideline - Masahiro Tsuboi, M.D., Ph.D. Associate-professor, School of Medicine,
More informationCooperative Group Update - Japan; JCOG & WJOG -
Cooperative Group Update - Japan; JCOG & WJOG - Masahiro Tsuboi, M.D., Ph.D. Associate-professor, School of Medicine, Yokohama City University Chief, Division of Thoracic Surgery, Respiratory Disease Center
More informationNivolumab: esperienze italiane nel carcinoma polmonare avanzato
NSCLC avanzato: quali novità nel 2018? Negrar, 30 Ottobre 2018 Nivolumab: esperienze italiane nel carcinoma polmonare avanzato Francesco Grossi UOC Oncologia Medica Fondazione IRCCS Ca Granda Ospedale
More informationTargeting CDK 4/6. Jee Hyun Kim, M.D., Ph.D. Seoul National University College of Medicine
2016.04.30 GBCC Education Symposium Targeting CDK 4/6 Jee Hyun Kim, M.D., Ph.D. Seoul National University College of Medicine Contents Cyclins -CDKs in cell cycle control CDK 4/6 in breast cancer Preclinical
More informationHER2-Targeted Rx. An Historical Perspective
HER2-Targeted Rx An Historical Perspective Trastuzumab: Front Line Rx for MBC Median 20.3 v. 25.1 mo P = 0.046 HR 0.8 65% of control patients crossed over Slamon D, et al. N Engl J Med, 2001; 344:783 Trastuzumab:Front-line
More informationSmall cell lung cancer. Targeted agents in SCLC
Small cell lung cancer Targeted agents in SCLC Enriqueta Felip Vall d Hebron University Hospital, Barcelona, Spain ESMO-The Christie Preceptorship program on Lung Cancer 03 March 2017 SCLC, where are we?
More informationSlide 1. Slide 2. Slide 3. Disclosures. Personalized Medicine for Advanced NSCLC in East Asia. No conflicts related to this presentation
Slide 1 12 th International Lung Cancer Conference Personalized Medicine for Advanced NSCLC in East Asia Masahiro Tsuboi, M.D., Ph.D. Group Chair, Lung Cancer Surgical Study Group in Japan Clinical Oncology
More informationCombining chemotherapy and radiotherapy of the chest
How to combine chemotherapy, targeted agents and radiotherapy in locally advanced NSCLC? Dirk De Ruysscher, MD, PhD Radiation Oncologist Professor of Radiation Oncology Leuven Cancer Institute Department
More informationHeather Wakelee, M.D.
Heather Wakelee, M.D. Assistant Professor of Medicine, Oncology Stanford University Sponsored by Educational Grant Support from Adjuvant (Post-Operative) Lung Cancer Chemotherapy Heather Wakelee, M.D.
More information1 st line chemotherapy and contribution of targeted agents in non-driver addicted NSCLC
1 st line chemotherapy and contribution of targeted agents in non-driver addicted NSCLC Dr Ross Soo, FRACP National University Cancer Institute, Singapore National University Health System Cancer Science
More informationSTUDY FINDINGS PRESENTED ON TAXOTERE REGIMENS IN HEAD AND NECK, LUNG AND BREAST CANCER
Contact: Anne Bancillon + 33 (0)6 70 93 75 28 STUDY FINDINGS PRESENTED ON TAXOTERE REGIMENS IN HEAD AND NECK, LUNG AND BREAST CANCER Key results of 42 nd annual meeting of the American Society of Clinical
More informationFoROMe Lausanne 6 février Anita Wolfer MD-PhD Cheffe de clinique Département d Oncologie, CHUV
FoROMe Lausanne 6 février 2014 Anita Wolfer MD-PhD Cheffe de clinique Département d Oncologie, CHUV Epithelial Ovarian Cancer (EOC) Epidemiology Fifth most common cancer in women and forth most common
More informationCommon disease 175,000 new cases/year 44,000 deaths/year Less than 10% with newly diagnosed at presentation have stage IV disease Chronic disease,
Chemotherapy for Metastatic Breast Cancer: Recent Results HARMESH R. NAIK, MD. Karmanos Cancer Institute and St. Mary Hospital Metastatic breast cancer (MBC) Common disease 175,000 new cases/year 44,000
More information